



**Troels Jordansen, Chief Executive Officer**



Troels Jordansen started his career in healthcare at LEO Pharma. After four years with Johnson & Johnson Orthopaedics he was one of the initial Genzyme Europe hires to focus on commercializing Carticel and Epicel in 1996. Over the past 20 years Jordansen has worked for five different cell therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd. and British Azellon Ltd. where he was co-founder. His roles have covered sales, marketing and general management; for the past 15 years he has been managing director and/or chairman for private and public listed companies. Jordansen has been part of award-winning management teams that have raised over €175 million in funding. He became Chairman of Glycostem in January 2014 and CEO in July 2016.



**Jan Spanholtz PhD, Chief Scientific Officer**



Dr. Jan Spanholtz initiated Glycostem's research in its start-up phase in 2007 and is currently its Chief Scientific Officer (CSO). Spanholtz has over 15 years of expertise in research on stem cell biology and immunology at universities and within biotech companies. He is the author of various peer-reviewed research articles and inventor of Glycostem's proprietary technology platform to generate oNKord<sup>®</sup> from umbilical cord blood stem cells. For Glycostem, he has set up and managed several national and international collaborations and spearheaded the clinical translational efforts of Glycostem's NK-cell product, oNKord<sup>®</sup>. Spanholtz developed the core IP strategy for Glycostem as inventor of the feeder cell-free NK-cell culture method from cord blood stem cells: a synthetic culture medium for NK-cells. He was also part of several other patent applications in the field of stem cell research.

more >



**Volker Huppert Dipl.-Ing., *Chief Development Officer***



Volker Huppert is a graduate bioprocess engineer from RWTH Aachen University. Among his achievements are participation in the set up of a quality system for a medical device/biotechnology company and development of several clinical-level reagents, disposable tubing sets and process software for cell separation and cell culture medical devices. He contributed to both the tubing set and process software development of a leading cell therapy-manufacturing device. Additionally, he managed projects and teams developing cell-manufacturing procedures for hematopoietic stem cells and Natural Killer cells. Huppert has published 12 papers in peer reviewed journals over the past 20 years while working for a leading biotechnology company and is co-inventor of 9 patent families, including methods for T cell depletion of hematopoietic stem cell products, NK-cell transduction and NK-cell proliferation.



**Kai Pinkernell, M.D., *Chief Medical Officer***



Kai Pinkernell has more than 20 years of experience in the development of cell and gene therapies and 15 years of senior management experience, including clinical development strategies and their execution at globally operating biotechnology companies. He has expertise in clinical marketing, sales, regulatory affairs, automation and GMP production of cellular therapies. In his previous role he operated as Chief Medical Officer and Chief Development Officer at Medigene AG, and prior to that as Global Head of Clinical Business at Miltenyi Biotec GmbH. Dr. Kai received his medical and Doctorate Degree from the Westfälische Wilhelms University of Muenster, Germany and MBA from the Marshall School of Business at the University of Southern California, Los Angeles, USA.



**Hans Henskens PhD, *Chief Quality Officer/QP***



Hans Henskens joined Glycostem's leadership team as Chief Quality Officer/QP in January 2020, bringing nearly 30 years of experience in the pharmaceutical industry to his role. During his career Hans played important roles such as the head of quality at Synthron Biopharmaceuticals BV, building the company's quality system; and as director of quality at PharmaCell BV, which was later acquired by Lonza Netherlands BV. Hans has extensive experiences in the field of cell therapy and virus transduced cell therapy products and has led several EMA and FDA inspections for different companies. Hans earned his PhD in molecular biology from the University of Amsterdam and has been acting as a Qualified Person within the European Union for the past 15 years.